Background: There are no randomized data evaluating the safety or efficacy of apixaban for
stroke prevention in patients with end-stage kidney disease on hemodialysis and with atrial …

Background: Non–vitamin K oral anticoagulants have become the standard therapy for
preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF) …

Background: Compared with the general population, patients with advanced chronic kidney
disease have a> 10-fold higher burden of atrial fibrillation. Limited data are available …

Background: Patients with end-stage kidney disease (ESKD) on dialysis were excluded from
clinical trials of direct oral anticoagulants for atrial fibrillation (AF). Recent data have raised …

Background Patients on long-term dialysis are at increased risk of bleeding. Although oral
anticoagulants (OACs) are recommended for atrial fibrillation (AF) to reduce the risk of …

Results Compared with no anticoagulation, apixaban was not associated with lower
incidence of the primary outcome: hazard ratio, 1.24; 95% confidence interval, 0.69 to 2.23; …

It is unclear whether warfarin is protective or harmful in patients with ESRD and atrial
fibrillation. This state of equipoise raises the question of whether alternative anticoagulants …

BACKGROUND: Apixaban is superior to aspirin for the prevention of stroke in patients with
atrial fibrillation. Apixaban is partially renally excreted and may accumulate in patients with …

Background There is a lack of clear benefit and a potential risk of bleeding with direct oral
anticoagulant (DOAC) use in chronic kidney disease (CKD) and dialysis patients with atrial …

Background At the present, apixaban is the only nonvitamin K oral anticoagulant approved
by the Food and Drug Administration for use with patients with creatinine clearance< 15 …